

REMARKS

The examiner is thanked for indicating withdrawal of the finality of the office action.

Claims 1, 3-6 and 10 are now rejected over Reynolds taken with Israel. Reconsideration of this rejection is again respectfully requested.


The office action indicates that claim 9 is free of the art. The features of claim 9 have also been incorporated in independent claim 10, thus rendering the rejection of this claim moot.

With respect to claim 1, it is submitted that this claim is non-obvious over the combination of the references. As will be recalled, Reynolds discloses a mixture of L-thyroxine and L-triiodothyroine, in free acid form. The disclosure also encompasses tablets containing active ingredients together with fillers such as lactose, starch and microcrystalline waxes. As noted previously by the office, Reynolds does not disclose the use of gelatin in such preparations. Israel discloses *injectable* pharmaceutical compositions for the parenteral administration of thyroxine, see column 1, lines 9-11. The disclosure teaches that thyroxine can be formulated for such parenteral administration in combination with a micro-molecular substance of a particular electrical charge. See page 1, lines 36-45. The authors indicate that such material may be a combination of gelatin *and* calcium gluconate, see page 1, lines 70-72. Thus, the teaching of this reference is of an injectable composition, i.e., a fluid, which may contain gelatin *only* in combination with calcium gluconate, which gelatin/calcium gluconate is added in order to avoid the thyrotoxicity associated with parenteral administration. See page 1, lines 22-35 and page 2, line 109-111. Present claim 1 does not encompass calcium gluconate, in view of the closed "consisting of" language.

It is accordingly respectfully submitted that all claims in the application are condition for allowance, and passage to issue is respectfully requested. However, should the examiner have any questions or comments, she is cordially invited to telephone the undersigned at the number below.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Harry B. Shubin, Reg. No. 32,004
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2168-D01

Date: November 228, 2006

HBS/blb

K:\Merck\2000 - 2999\2168\D1\amendment 11-29-06.doc